September 19th, 2017 MADISON, WI — Today FluGen Inc., a clinical stage vaccine company, announced that Dr. Robert Belshe was named Chairman of the Company’s Clinical Advisory Board (CAB). Along… read more →
MADISON – September 05, 2017 — FluGen Inc. announced today that C. Boyd Clarke has joined the Company as Executive Chairman effective immediately. Mr. Clarke will replace Dr. Dan Stinchcomb,… read more →
https://authors.elsevier.comM2SM2SR H5N1 2017 manuscriptR H5N1 2017 manuscript/sd/article/S0264410X17308265 Abstract The emergence of highly pathogenic avian influenza H5N1 viruses has heightened global concern about the threat posed by pandemic influenza. To address… read more →
FluGen generates funds – Judy Newman, Wisconsin State Journal FluGen has added $2 million to an investment round that began in August 2015. That puts the total amount raised in… read more →
FluGen Initiates a Phase 1 Clinical Trial of the RedeeFlu™ Universal Influenza Vaccine in Healthy Subjects MADISON, WI, July 27, 2016 – FluGen Inc., a clinical-stage biopharmaceutical company focused on… read more →